| Fallon Gokhman, PHARMD | |
|
1708 Park Ave, South Plainfield, NJ 07080-5519 | |
| (908) 755-7697 | |
| Not Available |
| Full Name | Fallon Gokhman |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1708 Park Ave, South Plainfield, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134724198 | NPI | - | NPPES |
| 28RI03955400 | Other | NJ | NJBOP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 28RI03955400 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Fallon Gokhman, PHARMD 596 Indian Rd, Wayne, NJ 07470-4918 Ph: () - | Fallon Gokhman, PHARMD 1708 Park Ave, South Plainfield, NJ 07080-5519 Ph: (908) 755-7697 |
News Archive
The appearance of objects can often change. For example, in dim evenings or fog, the contrast of the objects decreases, making it difficult to distinguish them.
Reza Zarnegar and colleagues, at the University of Pittsburgh, Pittsburgh, have determined that genetic variation in a piece of DNA that regulates activity of the HGF gene might be a useful marker to identify individuals with an increased risk of developing breast cancer.
Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is in continuing contract negotiations to acquire the rights to Integrated Optical Biosensor System (IBOS) technology developed by one of the U.S. Government's top national security research institutions.
The ribosome is a kind of factory for protein in the cell, and as such has long been a prime target for drug discovery. Now, a technological advance by a team at Weill Cornell Medical College is poised to revolutionize research in the field.
Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.
› Verified 5 days ago
Henry S Manalang, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4041 Hadley Rd Ste M, South Plainfield, NJ 07080 Phone: 908-222-1011 | |
Gail Story, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4041 Hadley Rd, Biulding M, South Plainfield, NJ 07080 Phone: 908-222-1011 Fax: 908-222-8877 | |
Jason Louie, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 913 Oak Tree Ave, South Plainfield, NJ 07080 Phone: 908-561-6677 | |
Bindumol Mathew, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4041 Hadley Rd, South Plainfield, NJ 07080 Phone: 908-222-1011 | |
Jessica Rivera, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4041 Hadley Rd, Suite M, South Plainfield, NJ 07080 Phone: 908-222-1011 Fax: 908-222-8877 | |
Linda Chiu, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1708 Park Ave, South Plainfield, NJ 07080 Phone: 908-755-7696 | |
Resha Patel, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2328 Plainfield Ave, South Plainfield, NJ 07080 Phone: 908-561-5848 |